3 months of uncertainty
Cancer immunotherapies are a rapidly growing market. But: Only 15–20% of cancer patients respond to immunotherapy - yet assessment takes at least 3 months. Our PET tracer enables early, precise insight into immune activity - before time and resources are lost.
2 weeks to clarity
Our patented MVP-stage PET-Tracer is able to visualize the immunotherapy itself within approximately two weeks by actively highlighting and visualizing the immune cells.
1 goal of helping patients
Our technology saves invaluable time for millions of cancer patients. Beyond that, it reduces costs for the healthcare system and helps pharma accelerate their drug development. imuveo has achieved Phase I clinical trial readiness and will soon impact the life of cancer patients worldwide.
Unlock the power of T-cell imaging - whether you're investing or innovating.
Shape the future of immunotherapy - join us in setting a new standard and backing our Phase 1 trial, as partner or investor.
-
The ecosystem is established and key players see the potential.
-
Every step along the way adds value to our project – and increases your ROI.
-
Boost your preclinical pipeline -add value to your biotech or pharma projects with precise T-cell tracking.